Relaxin receptor antagonist AT-001 synergizes with docetaxel in androgen-independent prostate xenografts
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Relaxin receptor antagonist AT-001 synergizes with docetaxel in androgen-independent prostate xenografts
Authors
Keywords
-
Journal
ENDOCRINE-RELATED CANCER
Volume 21, Issue 3, Pages 459-471
Publisher
Bioscientifica
Online
2014-05-09
DOI
10.1530/erc-14-0088
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide)
- (2013) M. Korpal et al. Cancer Discovery
- A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509
- (2013) J. D. Joseph et al. Cancer Discovery
- ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
- (2012) N. J. Clegg et al. CANCER RESEARCH
- Hypoxia-Induced Autophagy Promotes Tumor Cell Survival and Adaptation to Antiangiogenic Treatment in Glioblastoma
- (2012) Y.-L. Hu et al. CANCER RESEARCH
- Castration-resistant metastatic prostate cancer: current status and treatment possibilities
- (2012) Joan Carles et al. Clinical & Translational Oncology
- Subtleties in GPCR drug discovery: a medicinal chemistry perspective
- (2012) Masahiko Fujioka et al. DRUG DISCOVERY TODAY
- Proof-of-Concept Study of Monitoring Cancer Drug Therapy with Cerenkov Luminescence Imaging
- (2012) Y. Xu et al. JOURNAL OF NUCLEAR MEDICINE
- Resistance to CYP17A1 Inhibition with Abiraterone in Castration-Resistant Prostate Cancer: Induction of Steroidogenesis and Androgen Receptor Splice Variants
- (2011) Elahe A. Mostaghel et al. CLINICAL CANCER RESEARCH
- Tumor vessel stabilization and remodeling by anti-angiogenic therapy with bevacizumab
- (2011) Philip Weißhardt et al. HISTOCHEMISTRY AND CELL BIOLOGY
- Old issues and new perspectives on prostate cancer hormonal therapy: the molecular substratum
- (2011) Leonardo Oliveira Reis MEDICAL ONCOLOGY
- Reduced Expression of the Androgen Receptor by Third Generation of Antisense Shows Antitumor Activity in Models of Prostate Cancer
- (2011) Y. Zhang et al. MOLECULAR CANCER THERAPEUTICS
- Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma
- (2011) Olivier Keunen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Tumour Reactions to Hypoxia
- (2010) M.J. Voss et al. CURRENT MOLECULAR MEDICINE
- Suppression of relaxin receptor RXFP1 decreases prostate cancer growth and metastasis
- (2010) Shu Feng et al. ENDOCRINE-RELATED CANCER
- Docetaxel maintains its cytotoxic activity under hypoxic conditions in prostate cancer cells
- (2010) James C. Forde et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- The chemically synthesized human relaxin-2 analog, B-R13/17K H2, is an RXFP1 antagonist
- (2009) Mohammed Akhter Hossain et al. AMINO ACIDS
- Association of low tumor RNA integrity with response to chemotherapy in breast cancer patients
- (2009) Amadeo M. Parissenti et al. BREAST CANCER RESEARCH AND TREATMENT
- Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies
- (2009) Annamaria Rapisarda et al. DRUG RESISTANCE UPDATES
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started